Cytochrome P450 genotype polymorphisms and suboptimal voriconazole serum level in a patient with invasive cerebral fungal infection.
作者信息
Champagne William, Malek Alexandre E
机构信息
Division of Infectious Diseases, Department of Medicine, School of Medicine, LSU Health Shreveport, LA 71103, United States.
出版信息
IDCases. 2025 Jul 27;41:e02332. doi: 10.1016/j.idcr.2025.e02332. eCollection 2025.
Abstract
摘要
相似文献
1
Cytochrome P450 genotype polymorphisms and suboptimal voriconazole serum level in a patient with invasive cerebral fungal infection.
IDCases. 2025 Jul 27;41:e02332. doi: 10.1016/j.idcr.2025.e02332. eCollection 2025.
2
Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Eur J Clin Pharmacol. 2016 Oct;72(10):1185-1193. doi: 10.1007/s00228-016-2089-y. Epub 2016 Jul 8.
3
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Cochrane Database Syst Rev. 2014 Feb 24;2014(2):CD004707. doi: 10.1002/14651858.CD004707.pub3.
4
Impact of administration route and gene polymorphisms on the serum concentration of voriconazole among Chinese patients with hematologic malignancies.
Front Pharmacol. 2025 Jul 17;16:1445583. doi: 10.3389/fphar.2025.1445583. eCollection 2025.
5
The Effectiveness and Safety of Intravitreal Injections of Voriconazole in the Treatment of Fungal Endophthalmitis: A Systematic Review.
J Ocul Pharmacol Ther. 2024 Jul-Aug;40(6):332-341. doi: 10.1089/jop.2023.0103. Epub 2023 Nov 24.
6
Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights.
Clin Pharmacokinet. 2024 Nov;63(11):1609-1630. doi: 10.1007/s40262-024-01434-8. Epub 2024 Oct 30.
7
Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Clin Ther. 2022 Dec;44(12):1604-1623. doi: 10.1016/j.clinthera.2022.10.005. Epub 2022 Nov 22.
8
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Cochrane Database Syst Rev. 2006 Jan 25(1):CD004707. doi: 10.1002/14651858.CD004707.pub2.
9
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
J Antimicrob Chemother. 2007 Nov;60(5):1104-7. doi: 10.1093/jac/dkm330. Epub 2007 Sep 7.
10
Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Xenobiotica. 2017 Dec;47(12):1121-1129. doi: 10.1080/00498254.2016.1271960. Epub 2017 Jan 3.
本文引用的文献
1
Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.
Front Pharmacol. 2024 Sep 30;15:1292163. doi: 10.3389/fphar.2024.1292163. eCollection 2024.
2
Multidisciplinary Insights into the Structure-Function Relationship of the CYP2B6 Active Site.
Drug Metab Dispos. 2023 Mar;51(3):369-384. doi: 10.1124/dmd.122.000853. Epub 2022 Nov 23.
3
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6.
Drug Metab Pharmacokinet. 2021 Aug;39:100396. doi: 10.1016/j.dmpk.2021.100396. Epub 2021 Apr 12.
4
Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Ann Pharmacother. 2021 Apr;55(4):509-529. doi: 10.1177/1060028020948174. Epub 2020 Aug 8.
5
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Pharmacotherapy. 2020 Jan;40(1):17-25. doi: 10.1002/phar.2351.
6
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18.
7
Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.
8
Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
Int J Antimicrob Agents. 2014 Sep;44(3):183-93. doi: 10.1016/j.ijantimicag.2014.05.019. Epub 2014 Jul 7.
9
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Pharmacotherapy. 2014 Jul;34(7):703-18. doi: 10.1002/phar.1400. Epub 2014 Feb 7.
10
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.
Zotero 插件